Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTTR1147A Extension Study in Ulcerative Colitis or Crohn's Disease
NCT03650413Phase 2Terminated
- Sponsor
- Genentech
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 2 trial of efmarodocokin alfa in ulcerative colitis (UC), Crohn's disease, sponsored by Genentech. Started Jan 2019; status: terminated.
02
Drugs
efmarodocokin alfa
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03650413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650413.